ACLA Recognizes 30 Leading Patient and Consumer Organizations for Supporting RESULTS Act to Protect Access to Clinical Laboratory Testing
Washington, D.C. — The American Clinical Laboratory Association (ACLA) recognizes the 30 patient and consumer advocacy organizations representing millions of Americans who recently called on Congress to swiftly pass the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act (S. 2761 / H.R. 5269) to protect patient access to life-saving clinical laboratory testing services.
In a letter, these leading organizations representing patients with cancer, diabetes, kidney disease, autoimmune disorders, and other chronic and serious conditions emphasized: “Access to timely and accurate diagnostic health information is not optional—it is foundational to the health and well-being of millions of Americans. On behalf of patients across the country, we urge you to move swiftly to pass the RESULTS Act.”
This show of patient and consumer support follows a recent letter signed by ACLA and more than 30 provider organizations, including national laboratory, physician, hospital and health system, and diagnostic manufacturer groups. Together, the provider organizations called on Congress to enact the RESULTS Act to prevent destabilizing cuts to the Medicare Clinical Laboratory Fee Schedule (CLFS). The organizations also highlighted that “clinical laboratory tests inform 70 percent of medical decisions, yet the CLFS represents less than one percent of total Medicare spending.”
“Together, these 60 important organizations are a powerful, unified call from patients and providers urging Congress to act before the end of the year to protect access to clinical diagnostic testing,” said ACLA President Susan Van Meter. “We deeply appreciate the partnership of these organizations in recognizing the indispensable role of laboratory testing in modern medicine. The RESULTS Act is a commonsense, bipartisan solution that ensures access, innovation, and long-term stability for laboratory services.”
Without congressional action, clinical laboratories face up to 15 percent payment cuts on hundreds of widely used tests beginning January 31, 2026. The RESULTS Act would replace the outdated payment system with a modern, data-driven model that reflects commercial market rates, reduces administrative burden, and ensures continued innovation in diagnostics.
ACLA and its members also continue to mobilize support through the Stop Lab Cuts campaign, which has already generated more than 150,000 messages to lawmakers urging action to protect access to timely, reliable, and high-quality laboratory testing. Visit StopLabCuts.org to learn more.
The letter is here and the complete list of signatories is below:
Alliance for Aging Research
Alliance for Patient Access
Alliance for Women’s Health and Prevention
Alzheimer’s Association
Alzheimer’s Impact Movement (AIM)
American Cancer Society Cancer Action Network
American Sexual Health Association
Applied Pharmacy Solutions
Axis Advocates
Black Women’s Health Imperative
California Chronic Care Coalition
CancerCare
Caregiver Action Network
Center for Patient Advocacy Leaders
Cholangiocarcinoma Foundation
Chronic Care Policy Alliance
Community Liver Alliance
Family Heart Foundation
Gerontological Society of America
GO2 for Lung Cancer
Healthcare Institute of New JerseyHealthy Women
ICAN, International Cancer Advocacy Network
LUNGevity Foundation
Lupus and Allied Disease Association, Inc.
Minority Health Institute, Inc.
The National Association of Directors of Nursing Administration
National Grange
National Health Council
Neuropathy Action Foundation
Partnership to Fight Chronic Disease
Retire Safe
Sepsis Alliance
Solve M.E.
###
The American Clinical Laboratory Association (ACLA) is the national trade association representing leading laboratories that deliver essential diagnostic health information to patients and providers by advocating for policies that expand access to the highest quality clinical laboratory services, improve patient outcomes, and advance the next generation of personalized care.
